BDSI buys US rights to BEMA (bioerodible mucoadhesive disc) drug tech
This article was originally published in Clinica
Executive Summary
BioDelivery Sciences International (BDSI) has acquired the US rights to the BEMA (bioerodible mucoadhesive disc) drug delivery technology developed by biopharmaceutical company QLT for $3m. BDSI has also agreed to pay QLT up to $4m for achieving certain milestones, one of these being the NDA approval of BDSI's first BEMA product.
You may also be interested in...
Lannett Plans Seven Launches In Fiscal Year 2021
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer Picks Up EU Pegfilgrastim Approval
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
A Stroke Of Luck Boosts Oxford/AZ’s “Vaccine For The World”
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: